HLA-C and neoplasm: TCR-T therapy, which engineers T cells to target MHC-presented intracellular antigens, offers deeper tumor penetration but is constrained by human leukocyte antigen (HLA) matching, off-target toxicity risks, and limited antigen availability (163–166).